In vivo quantification of the sigma1-receptor availability by means of Positron Emission Tomography (PET) in depressed subjects and healthy controls
- Conditions
- DysthymiaF34.1F31.3F31.4F31.5F32F33Bipolar affective disorder, current episode mild or moderate depressionBipolar affective disorder, current episode severe depression without psychotic symptomsBipolar affective disorder, current episode severe depression with psychotic symptoms
- Registration Number
- DRKS00008321
- Lead Sponsor
- niversität Leipzig
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 45
age between 18 and 65 years
- caucasian
- without psychotropic medication for at least 2 weeks before PET
- patients with depressive disorder and healthy controls
- significant cerebral lesions
- stroke, cocussion, severe subcortical arteriosclerotic encephalitis, multiple sclerosis, brain tumor, dementia, Parkinsons disease
- pregnancy, breast-feeding
- legally incopetent persons
- impaired medical conditions (instable angina pect
oris, recent mycardial infarct, malignant disease)
- severely impaired sight or hearing abilitiy
- contraindications for MRT (metal implants e.g.)
for healty controls: participation in a study for diagnostic or therapeutic purpose by means of ionising radiation within the last 10 years,. if an effective radiation dose of more than 10 mSv can be expected
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Examination of the central sigma-1-receptor availibility in patients with major depressive disorder compared to healthy controls using (-)-[18F]Flusipidine and PET
- Secondary Outcome Measures
Name Time Method - correlation analyses between neuro-psychometric scales, genetic variables and PET-data<br>- data of safety and tolerability of (-)-[18F]Fluspidine <br>- development of a kinetic model for analysis of (-)-[18F]Fluspidine PET data